Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

This study has been completed.
Janssen-Cilag Ltd.
Information provided by (Responsible Party):
Institut Claudius Regaud Identifier:
First received: September 13, 2005
Last updated: November 23, 2011
Last verified: November 2011
The purpose of this study is to determine the efficacy by the determination of the Time To Progression (TTP) in patients with resectable GBM or non surgical GBM with a size less than 5 cm treated with the combination of ZARNESTRA plus Radiation therapy.

Condition Intervention Phase
Glioblastoma Multiforme
Drug: Zarnestra
Procedure: standard Radiation therapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

Resource links provided by NLM:

Further study details as provided by Institut Claudius Regaud:

Primary Outcome Measures:
  • Efficacy will be assessed by the determination of the Time To Progression (TTP) in patients with resectable GBM or non surgical GBM with a size less than 5 cm treated with the combination of ZARNESTRA plus Radiation therapy [ Time Frame: time of study ]

Secondary Outcome Measures:
  • Objective response rate (RECIST and volumetric criteria) [ Time Frame: time of study ]
  • Median survival, 6 month and 1 year survival rates [ Time Frame: 6 month and 1 year ]
  • Safety of combination therapy of ZARNESTRA and RT, based on laboratory and clinical parameters [ Time Frame: time of study ]

Enrollment: 27
Study Start Date: October 2005
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Zarnestra
    ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.
    Procedure: standard Radiation therapy
    Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have pathologically confirmed (histology or cytology), resectable or non resectable, glioblastoma multiforme with a size < 5 cm on MRI if non resectable
  • Patients must be at least 7 days but no more than 2 months since surgery or biopsy.
  • Patients must have an ECOG Performance Status ≤ 2.
  • Patients must be aged 18
  • Patient has signed the informed consent form

Exclusion Criteria:

  • Patients with unresectable glioblastoma with a size >5 cm on MRI
  • Patients with clinically apparent leptomeningeal metastases
  • Patients with uncontrolled seizures despite standard anticonvulsant therapy
  • Any prior systemic treatment (chemotherapy, immunotherapy, hormonal therapy) for glioblastoma multiforme
  • Significantly abnormal haematological status as judged by:

Absolute neutrophil count (ANC) < 1500/mm3 (1.5*109/l) Platelet count <100,000/mm3 (100*109/l)

  • Serum bilirubin >2 mg/dl (>34 mmol/l) or Transaminase >2.5x the upper limit of institutional normal or Creatinine >1.5 mg/dl (>132 mmol/l)
  • Inability to co-operate with the treatment protocol
  • Patients who cannot undergo imaging evaluations
  • Participation in an investigational drug trial in the 30 days prior to selection
  • Pregnant or nursing mothers. (Female patients of childbearing potential must use adequate contraception.)
  • Any malignancy within the past five years. Exceptions are: superficial basal cell carcinoma or non-metastatic squamous cell cancer of the skin, cervix cancer (cervical intra-epithelial neoplasia -CIN or FIGO stage 1) or prostate intra-epithelial neoplasia (PIN), biochemical relapse free for at least 3 years.
  • Any prior systemic chemotherapy in the past five years for any malignancy in the medical history
  • Any concurrent disease that in the opinion of the investigator would constitute a hazard for participating in this study
  • Known sensitivity to imidazole derivatives
  • Patients under law protection
  • Medical history of phlebitis or pulmonary embolism, thrombocytosis, myocardiopathy, or other relevant cardiac pathology (auricular flutter, auricular fibrillation)
  • Medical history of immuno-allergic pneumopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00209989

Centre Jean Perrin
Clermont Ferrand, France
Institut Claudius Regaud
Toulouse, France
Sponsors and Collaborators
Institut Claudius Regaud
Janssen-Cilag Ltd.
Principal Investigator: Elizabeth MOYAL, Dr Institut Claudius Regaud
  More Information

Responsible Party: Institut Claudius Regaud Identifier: NCT00209989     History of Changes
Other Study ID Numbers: 02 TETE 02
Study First Received: September 13, 2005
Last Updated: November 23, 2011

Keywords provided by Institut Claudius Regaud:
Glioblastoma Multiforme
Radiation therapy

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents processed this record on May 25, 2017